retatrutide for diabetes Promises Big Weight Loss, but Safety Remains a Question What is Retatrutide? Is it

Serious side effects and warnings Retatrutide does not currently have an FDA-approved boxed warning, contraindication section, or final adverse-reaction profile because it is not FDA-approved

A peptide that activates two is a dual agonist

The GLP-1 Phenomenon: Current Duopoly The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists has started a ( new ) golden era for the pharmaceutical industry

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Market Why Did the Injectable Segment Dominate in the GLP-1 Drugs Market in 2025

They promise the benefits of modern medicine without the needles or strict regulations